Irish Drugmaker Actavis In Talks To Buy Forest Labs For $25B
International Business Times
Published Feb 18, 2014 07:07AM ET
Updated Feb 18, 2014 07:25AM ET
By Sneha Shankar - Actavis PLC (NYSE:ACT) is in advanced talks to buy out competing drug maker Forest Labs (NYSE:FRX) in a whopping $25 billion deal expected to be announced early Tuesday, according to media reports.
The acquisition of New York-based Forest Labs, which had a market capitalization of $19.3 billion as of Friday, would add a range of generic drugs including Alzheimer’s drug,Namenda, and blood-pressure pill, Bystolic, to Actavis’ product line-up. On Feb. 14, Actavis had a market value of $33.4 billion.
Dublin-based Actavis has made deals worth $14.4 billion over the last three years and reportedly uses the mergers and acquisitions route to grow inorganically, a Bloomberg report said, citing Ori Hershkovitz, a partner at Sphera Funds Management Ltd in Tel Aviv.
“They have promised the market that they would do a large amount of deals to keep the accretion alive. If you can’t do a large amount of R&D, there’s only one way to grow and that’s through M&A,” Hershkovitz said, according to Bloomberg.
The transaction has not been confirmed by either company but the speculated $25 billion deal value is more than seven times Forest Labs' estimated sales for 2014, according to Bloomberg.
In October, the company bought New Jersey-based Warner Chilcott Plc. for $9.2 billion to expand into the women's health segment.
Forest Labs' stock, which closed 1.49 percent up on Friday was trading 23.27 percent up in pre-market trading Tuesday.
Get The News You Want
Written By: International Business Times
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.